BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35884510)

  • 1.
    Versemann L; Patil S; Steuber B; Zhang Z; Kopp W; Krawczyk HE; Kaulfuß S; Wollnik B; Ströbel P; Neesse A; Singh SK; Ellenrieder V; Hessmann E
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
    Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
    Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer.
    Patil S; Forster T; Reutlinger K; Kopp W; Versemann L; Spitalieri J; Gaedcke J; Ströbel P; Singh SK; Ellenrieder V; Neesse A; Hessmann E
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant NFATc1 signaling counteracts TGFβ-mediated growth arrest and apoptosis induction in pancreatic cancer progression.
    Hasselluhn MC; Schmidt GE; Ellenrieder V; Johnsen SA; Hessmann E
    Cell Death Dis; 2019 Jun; 10(6):446. PubMed ID: 31171768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
    Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
    Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
    Li CH; Xiao Z; Tong JH; To KF; Fang X; Cheng AS; Chen Y
    Int J Cancer; 2017 Jan; 140(1):120-129. PubMed ID: 27594424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
    Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
    Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance.
    Chibaya L; Murphy KC; DeMarco KD; Gopalan S; Liu H; Parikh CN; Lopez-Diaz Y; Faulkner M; Li J; Morris JP; Ho YJ; Chana SK; Simon J; Luan W; Kulick A; de Stanchina E; Simin K; Zhu LJ; Fazzio TG; Lowe SW; Ruscetti M
    Nat Cancer; 2023 Jun; 4(6):872-892. PubMed ID: 37142692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by
    Hu S; Chen X; Xu X; Zheng C; Huang W; Zhou Y; Akuetteh PDP; Yang H; Shi K; Chen B; Zhang Q
    Front Oncol; 2020; 10():594224. PubMed ID: 33134183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice.
    Young CC; Baker RM; Howlett CJ; Hryciw T; Herman JE; Higgs D; Gibbons R; Crawford H; Brown A; Pin CL
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):93-113. PubMed ID: 30510993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma.
    Han T; Zhuo M; Yuan C; Xiao X; Cui J; Qin G; Wang L; Jiao F
    Cancer Biol Med; 2020 Nov; 17(4):953-969. PubMed ID: 33299646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
    Zhang Y; Tong T
    Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Therapeutic Strategies to Target Molecular and Cellular Heterogeneity in Pancreatic Cancer.
    Versemann L; Hessmann E; Ulisse M
    Visc Med; 2022 Feb; 38(1):11-19. PubMed ID: 35291698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2-shRNA-mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma.
    Batchu RB; Qazi AM; Gruzdyn OV; Semaan A; Seward SM; Chamala S; Dhulipala VB; Bouwman DL; Weaver DW; Gruber SA
    Surgery; 2013 Oct; 154(4):739-46; discussion 746-7. PubMed ID: 24074410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of long noncoding RNA SNHG14 suppresses cell proliferation and invasion by regulating EZH2 in pancreatic ductal adenocarcinoma (PDAC).
    Xie F; Huang Q; Wang C; Chen S; Liu C; Lin X; Lv X; Wang C
    Cancer Biomark; 2020; 27(3):357-364. PubMed ID: 31929143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
    Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
    J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
    Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
    Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
    [No Abstract]   [Full Text] [Related]  

  • 20. Laser capture microdissection of pancreatic ductal adeno-carcinoma cells to analyze EzH2 by Western Blot analysis.
    Qazi AM; Aggarwal S; Steffer CS; Bouwman DL; Weaver DW; Gruber SA; Batchu RB
    Methods Mol Biol; 2011; 755():245-56. PubMed ID: 21761309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.